Psyence Biomedical Ltd. (PBM) stock
Close on Oct 19, 2026Market cap –P/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Mar 31, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- EPS, diluted
- -$12.56
- Free cash flow
- -$8.14M
Trading
- Previous close
- $4.22
- Open
- $4.09
- Day's range
- $4.08 – $4.28
- Volume
- 34,533
- Average volume (20 days)
- 70,968
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | PBM | S&P 500 | Difference | PBM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -37.8% | +0.6% | −38.4 pts | ||
| 3 months | +34.2% | +3.4% | +30.8 pts | ||
| Year to date | +446.9% | +13.3% | +433.6 pts | ||
| 1 year | +17.0% | +16.6% | +0.4 pts | ||
| 3 years | -99.9% | +86.4% | −186.3 pts | -91.5% | +23.1% |
Five years at a glance
Fiscal years 2022 to 2026, USD
EPS, diluted
Free cash flow
Press releases
Releases Psyence Biomedical filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Psyence Biomedical
Pharmaceutical Preparations
Psyence Biomedical Ltd. is a clinical-stage biotechnology company that focuses on the research and development of psychedelic therapies. The company develops drug candidates featuring psychedelic compounds, primarily psilocybin-based therapeutics and related chemical analogs. Its product pipeline is currently in preclinical and clinical stages, with indications focused on mental health conditions such as serious mental illnesses. Psyence operates within the biopharmaceutical sector, licensing intellectual property and advancing clinical trials in collaboration with research partners. Once approved, its therapeutic candidates target patients in need of psychiatric treatments, along with healthcare providers and prescribing physicians.
Company profile, executives and historyPsyence Biomedical stock: common questions
What is Psyence Biomedical's stock price?
PBM closed at $4.12 on Oct 19, 2026, down 2.37% on the day.
What is PBM's P/E ratio?
Psyence Biomedical lost money over fiscal 2026 (diluted EPS -$12.56), so it has no meaningful P/E ratio.
Does Psyence Biomedical pay a dividend?
No. Psyence Biomedical has not paid a cash dividend over the last twelve months.
How has PBM stock performed over the past year?
Including dividends, PBM returned +17.0% over the past year, against +16.6% for the S&P 500.
Who are Psyence Biomedical's competitors?
Companies most similar to Psyence Biomedical by business, industry and size include MSLE, CMPS, IXHL, XTLB, KZIA.
See a number that looks wrong?